Home
Resources
Publications
RSV604, a Novel Inhibitor of Respiratory Syncytial Virus Replication

RSV604, a Novel Inhibitor of Respiratory Syncytial Virus Replication

Joanna Chapman, Elizabeth Abbott, Dagmar G Alber, Robert C Baxter, Sian K Bithell, Elisa A Henderson, Malcolm C Carter, Phil Chambers, Ann Chubb, G Stuart Cockerill, Peter L Collins, Verity C L Dowdell, etc.

Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53.

PMID: 17576833

Abstract:

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available. Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity. It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP676128635	RSV604		676128-63-5	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: